Immune Response of Haemodialysis Patients Post Covid-19 Vaccination

The Malaysian Study On Hemodialysis Patients SARS-COV-2 Vaccination Immune Response: A Prospective Observational Cohort Study

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT04872751

Acronym

Covid-19

Enrollment

425

Registered

2021-05-04

Start date

2021-04-27

Completion date

2022-04-30

Last updated

2021-05-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Immune Response Post Covid 19 Vaccination

Brief summary

The purpose of this study is to assess immune response of end stage renal failure patients after Covid 19 vaccination

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* ESRF patient on hemodialysis who are eligible for the goverment Covid 19 vaccination programme * 18 years old and above * consented to join the study

Exclusion criteria

* patient who refused to be vaccinated * patient who deemed unsuitable for Covid vaccination

Design outcomes

Primary

Measure	Time frame	Description
Change From Baseline in post vaccination SARS-CoV-2 neutralizing antibody level	up to one year	Study the antibody synthesis induced by vaccination, among end stage renal failure patients, and the change in its level at 1 month, at 6 months and at 1 year after complete vaccination.

Secondary

Measure	Time frame	Description
Change From Baseline in post vaccination SARS-CoV-2 neutralizing antibody level after 1st inoculation of the vaccine (incomplete vaccination)	one month	Study the antibody synthesis and the change in its level after 1st inoculation of the vaccine

Countries

Malaysia

Contacts

Primary ContactXueFang Tan

xf821020@hotmail.com6042225333

Outcome results